Clinical Observation of Macrolide Therapy in the Treatment of Chronic Rhinosinusitis

ZHOU Hao,CHEN Bing
DOI: https://doi.org/10.7507/1002-0179.20130013
2013-01-01
Abstract:Objective To examine the clinical effect of low-dose macrolide on the treatment of chronic rhinosinusitis(CRS).Methods Fifty-six patients diagnosed to have CRS between July 2009 and December 2011 were recruited.Among these patients,20 were accompanied with polyps,while the other 36 were not.The diagnosis criteria was Diagnosis and Therapy Guideline for CRP(Nanchang,2008).All patients were given Klacid at 250 mg/d orally for at least 12 weeks.The clinical efficacy was subjectively and objectively evaluated with visual analogue scale(VAS),nasal endoscopy by Lund-Kennedy scoring system,and Lund-Mackay CT scoring system before treatment,at the end of treatment,and three months after the treatment.Results For CRS patients without polyps,the VAS score,Lund-Kennedy score and Lund-Mackay CT score at the end of treatment were 2.56±1.09,2.08±1.03,and 2.43 ± 1.81,respectively,which were all significantly lower than those before treatment: 7.63 ± 2.16(P<0.01),6.10 ± 1.98(P<0.01),and 6.86 ± 2.32(P<0.01).During the three months after treatment,no recurrent sinusitis happened.For CRS patients with polyps,the VAS score at the end of treatment was 4.13 ± 1.86,significantly lower than that before treatment: 8.22 ± 2.67(P<0.05).However,Lund-Kennedy score and Lund-Mackay CT score in these patients were not significantly different from those before treatment(8.56 ± 2.54 and 6.88 ± 2.38,P>0.05;14.28 ± 3.43 and 13.46 ± 3.82,P>0.05).No side effect occurred in any patients.Kidney function of all patients were not influenced either.Conclusions It is effective to treat CRS patients without polyps by a low-dose(250 mg/d),long-term(12 weeks) Klacid.However,simple Klacid therapy on CRP patients with polyps is unsatisfied.Klacid is well tolerated and safe to CRS patients.
What problem does this paper attempt to address?